AZN

Astrazeneca plc

Jun 23 • 04:00PM ET

181.02

+4.59 2.60 %

Healthcare • Drug Manufacturers - General • United Kingdom • Mega • NYSE

Peers: LLY MRK PFE ABBV JNJ NVS GSK BMY SNY AMGN

| Held by: PVAL AVDE DIHP DFIC PPH IDVO PBPH FVD DFAX BDYN

Index	-	P/E	27.20	EPS (ttm)	6.66	Insider Own	3.45%	Shs Outstand	1.55B	Perf Week	2.12%
Market Cap	280.74B	Forward P/E	15.51	EPS next Y	11.67	Insider Trans	-0.02%	Shs Float	1.50B	Perf Month	-4.60%
Enterprise Value	307.03B	PEG	1.25	EPS next Q	2.50	Inst Own	62.13%	Short Float	0.11%	Perf Quarter	-1.66%
Income	10.39B	P/S	4.64	EPS this Y	12.28%	Inst Trans	-14.72%	Short Ratio	0.87	Perf Half Y	0.27%
Sales	60.44B	P/B	5.93	EPS next Y	13.50%	ROA	9.43%	Short Interest	1.72M	Perf YTD	3.15%
Book/sh	30.52	P/C	36.58	EPS next 5Y	12.45%	ROE	23.51%	52W High	212.71 -14.90%	Perf Year	27.47%
Cash/sh	4.95	P/FCF	24.02	EPS past 3/5Y	45.90% 22.05%	ROIC	14.17%	52W Low	134.90 34.19%	Perf 3Y	23.86%
Dividend Est.	3.35 (1.85%)	EV/EBITDA	15.46	Sales past 3/5Y	9.82% 16.31%	Gross Margin	74.32%	Volatility	1.55% 1.67%	Perf 5Y	55.75%
Dividend TTM	3.20 (1.77%)	EV/Sales	5.08	EPS Y/Y TTM	33.66%	Oper. Margin	23.23%	ATR (14)	3.80	Perf 10Y	217.02%
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	0.71	Sales Y/Y TTM	9.93%	Profit Margin	17.19%	RSI (14)	48.97	Recom	1.55
Dividend Gr. 3/5Y	1.78% 3.25%	Current Ratio	0.91	EPS Q/Q	5.63%	SMA20	0.11%	Beta	0.30	Target Price	223.30
Payout	47.19%	Debt/Eq	0.72	Sales Q/Q	12.51%	SMA50	-2.70%	Rel Volume	0.76	Prev Close	176.43
Employees	96100	LT Debt/Eq	0.55	Earnings	Apr 29 BMO	SMA200	-0.31%	Avg Volume	1.97M	Price	181.02
IPO	Oct 17, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.34% 2.38%	Trades		Volume	1,492,848	Change	2.60%

Jun-23-26 09:00PM	CelLBxHealth PLC (ANPCF) Full Year 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
02:18AM	FTSE 100 Live: London stocks inch higher as Wall Street tech sells off (Proactive)
Jun-22-26 04:51AM	Eco Buildings, Solvonis Therapeutics, CelLBxHealth, NextEnergy Solar Fund, Empire Metals, Coinsilium (Proactive)
Jun-19-26 05:30AM	CelLBxHealth CEO on strategy reset and growth plans (Proactive)
05:13AM	ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain (Pharmaceutical Technology)
04:49AM	Loading…
04:49AM	European stocks edge higher, helped by energy and healthcare (Reuters)
Jun-17-26 08:00AM	Big pharma taps UK playbook to pressure Europe on drug prices (Reuters Videos)
Jun-15-26 03:46PM	EHA26: AstraZeneca battles Roche in untreated follicular lymphoma (Clinical Trials Arena)
07:06AM	Factbox-Global drugmakers rush to boost US presence as tariff threat looms (Reuters)
Jun-10-26 05:12AM	AstraZenecas extensive obesity drug push; $125M for ultrasound-aided genetic medicine (BioPharma Dive)
Jun-09-26 10:10AM	GSK Buys Nuvalent for $10.6 Billion in Major Cancer Push (Bloomberg)
Jun-08-26 06:25PM	AstraZeneca's GLP-1 Pill Clears Early Hurdle in Diabetes, Obesity Tests (The Wall Street Journal)
05:32PM	LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZenecas Therapies In Diabetes Trials (Stocktwits)
Jun-06-26 02:53PM	Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy. (MarketWatch)
Jun-05-26 11:00AM	AstraZeneca CFO Dr. Aradhana Sarin Breaks Down Revenue Growth Goals (NYSE)
11:00AM	Loading…
11:00AM	AstraZeneca Pascal Soriot Delivers Remarks as Firm Celebrates Transfer to NYSE (NYSE)
08:55AM	NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History (PR Newswire)
Jun-03-26 11:00PM	A Spanish biotech banks $87M to make differentiated ADCs (BioPharma Dive)
06:32AM	Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions (Proactive)
Jun-01-26 10:19AM	AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early CEO Sees 'Value-Inflection Period' Ahead (Stocktwits)
10:19AM	AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule CEO Sees 'Significant Value-Inflection Period' Ahead (Stocktwits)
09:57AM	ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do (Proactive)
05:06AM	AstraZeneca aims for a new blockbuster run in cardio disease (Pharma Voice)
May-29-26 10:33AM	US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial (Proactive)
06:17AM	Allogene CEO to step down; Agios drug fails key test (BioPharma Dive)
May-28-26 02:16AM	FTSE 100 Live: London stocks flop as oil and bonds kick back up on Hormuz tensions (Proactive)
May-27-26 11:30PM	SLS Stock Extends Rally Overnight: CEO Says Bullish Leukemia Data Could Drive NCCN Recognition For GPS (Stocktwits)
10:09AM	FDA delays decision on AstraZeneca breast cancer pill (BioPharma Dive)
May-26-26 06:16AM	Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine (BioPharma Dive)
May-25-26 06:06AM	AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC (Pharmaceutical Business Review)
05:38AM	Loading…
May-21-26 05:38AM	Lillys triple-acting obesity drug hits goal in Phase 3 trial (BioPharma Dive)
May-20-26 05:06AM	Big Pharma is gambling on specialized R&D. Will it pay off? (Pharma Voice)
May-18-26 09:02AM	AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug (GuruFocus.com)
08:04AM	FDA approves AstraZenecas new kind of hypertension drug (BioPharma Dive)
07:00AM	BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension (Business Wire)
02:53AM	AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu (Proactive)
02:15AM	FTSE 100 Live: Stocks spike on reports of progress in Iran-US negotiations (Proactive)
May-15-26 07:36AM	Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive)
May-14-26 07:00AM	Perioperative IMFINZI (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial (Business Wire)
May-13-26 07:28AM	UAE approves AstraZeneca's Baxfendy for hypertension (Pharmaceutical Business Review)
05:00AM	Why the FDAs push for real-time clinical trials could favor Big Pharma (Pharma Voice)
02:17AM	FTSE 100 Live: London stocks in red, Babcock gains offset by bond worries over Starmer (Proactive)
May-11-26 06:00PM	PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact (GuruFocus.com)
May-07-26 11:34AM	Why This Income Pro Likes Banks, Chip-Equipment Companies, and More (Barrons.com)
May-06-26 07:07PM	Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions (GuruFocus.com)
May-01-26 08:28AM	Summits self-inflicted stumble; Esperions take-private deal (BioPharma Dive)
08:10AM	AstraZeneca stock sinks after FDA advisers vote against its breast cancer drug (Quartz)
08:01AM	AstraZeneca stock falls after FDA panel rejects breast cancer drug (Quartz)
05:48AM	AstraZeneca shares drop after US regulators vote against breast cancer drug (Reuters Videos)
04:46AM	AstraZeneca falls as FDA advisers reject breast cancer drug use (Proactive)
04:06AM	AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant (Investing.com)
Apr-30-26 09:42PM	TRUQAP (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer (Business Wire)
08:32AM	Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts (Proactive)
Apr-29-26 07:00PM	Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca (PR Newswire)
12:12PM	AstraZeneca to invest £300m in Britain as Starmer pays more for drugs (The Telegraph)
11:12AM	AstraZeneca beats Q1 estimates, CEO says drug pipeline is 'delivering' (Yahoo Finance Video)
08:06AM	Astrazeneca tops expectations in the first quarter on strong cancer drug sales (Associated Press)
07:58AM	AstraZeneca Q1 2026 earnings beat on cancer drug sales (Quartz)
07:21AM	FDA tests out real-time clinical trials; AbbVie closes in on a KRAS biotech (BioPharma Dive)
06:09AM	American industry is winning: White House touts factory boom how investors can ride the reshoring wave (Moneywise)
03:09AM	AstraZeneca tops Q1 forecasts on strong cancer, rare-disease drug demand (Investing.com)
02:36AM	Astrazeneca: Q1 Earnings Snapshot (Associated Press)
02:16AM	FTSE 100 Live: Stocks sink as oil pushes 4yr highs, AstraZeneca, GSK, Lloyds report (Proactive)
02:16AM	FTSE 100 Live: Sluggish start as AstraZeneca, Haleon results disappoint (Proactive)
02:03AM	AstraZeneca sticks to its guns after strong first-quarter revenue growth (Proactive)
Apr-28-26 03:00PM	FDA is launching real-time monitoring of drug trials, with AstraZeneca and Amgen as first test cases (Quartz)
09:15AM	Earnings To Watch: AstraZeneca PLC (LSE:AZN) Reports Q1 2026 Result (GuruFocus.com)
05:55AM	FDA approves AstraZeneca's Saphnelo for SLE (Pharmaceutical Business Review)
02:06AM	FTSE 100 Live: Barclays leads blue-chips lower after results, oil hits $110 a barrel (Proactive)
Apr-27-26 08:04AM	Citi sees Daiichi supply review as immaterial for AstraZeneca (Proactive)
07:00AM	SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus (Business Wire)
Apr-21-26 01:01PM	T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage (GuruFocus.com)
08:03AM	AstraZeneca's tozorakimab treble puts $5bn sales ceiling in sight, says Citi (Proactive)
03:16AM	AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial (Proactive)
02:16AM	FTSE 100 Live: Stocks open flat as market awaits signals on Iran-US talks (Proactive)
02:16AM	FTSE 100 Live: London stocks mixed as bond markets eye Starmer pressure (Proactive)
Apr-20-26 07:00AM	Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD (Business Wire)
Apr-17-26 06:44AM	The innovators working to make in vivo cell therapy a reality (Pharmaceutical Technology)
Apr-15-26 03:17AM	FTSE 100 Live: Shares mixed as Iran talks awaited, Ceres and Rank jump (Proactive)
Apr-13-26 12:48PM	GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% (GuruFocus.com)
Apr-10-26 05:01PM	Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage (GuruFocus.com)
10:31AM	AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside (Proactive)
Apr-08-26 08:09AM	Virginia governor signs 4 laws establishing manufacturing grant programs (Manufacturing Dive)
Apr-07-26 07:15AM	FTSE 100 Live: Defence and gold miners drag as Trump's new Iran deadline awaited (Proactive)
07:00AM	AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug (Proactive)
Apr-01-26 09:15AM	US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results (Proactive)
Mar-31-26 03:45PM	$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA (Exec Edge)
09:04AM	Lilly's $2 Billion AI Deal Raises Stakes (GuruFocus.com)
Mar-30-26 10:15AM	Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients (Proactive)
05:23AM	FTSE 100 Live: Blue-chip index climbs as oil price rises but bonds ease (Proactive)
02:03AM	Connecting Excellence Group appoints chief performance and growth officer (Proactive)
Mar-27-26 07:00AM	Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD (Business Wire)
04:41AM	AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials (Proactive)
Mar-26-26 03:00PM	Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-24-26 10:30AM	Advancements in Novel Immunotherapeutics in The Oncology Battle (Newsfile)
Mar-19-26 11:39AM	Long-only funds are buying non-US stocks, BofA says (Investing.com)
03:22AM	AstraZeneca to boost cell therapy capabilities with new China investment (BioPharma Dive)
Mar-18-26 02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
Mar-16-26 07:02AM	Building materials giant abandons London stock market (The Telegraph)
07:02AM	£50bn construction giant abandons London stock market (The Telegraph)

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.

CFO & Executive DirectorDr. Aradhana Sarin M.D.

EVP of Global opt. & ITMs. Pam P. Cheng

Head of Investor RelationsMr. Joris Silon

CHROMr. Jeffrey Pott J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sharma Mani	See Remarks	May 20 '26	Sale	185.78	11,893	2,209,482	19,262	May 22 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc

Upgrade your Finviz experience